These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32048198)

  • 1. Patient-Reported Outcomes in Myelodysplastic Syndromes: the Move from Life Span to Health Span.
    Barot SV; Patel BJ; Gerds AT
    Curr Hematol Malig Rep; 2020 Apr; 15(2):149-154. PubMed ID: 32048198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times.
    Patel SS; Gerds AT
    Curr Hematol Malig Rep; 2017 Oct; 12(5):455-460. PubMed ID: 28822056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing Quality of Care for the Myelodysplastic Syndromes.
    Frosch ZA; Abel GA
    Curr Hematol Malig Rep; 2016 Dec; 11(6):402-407. PubMed ID: 27562670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group.
    Rochau U; Stojkov I; Conrads-Frank A; Borba HH; Koinig KA; Arvandi M; van Marrewijk C; Garelius H; Germing U; Symeonidis A; Sanz GF; Fenaux P; de Witte T; Efficace F; Siebert U; Stauder R
    Br J Haematol; 2020 Nov; 191(3):405-417. PubMed ID: 32410281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
    Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
    BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned?
    Cannella L; Caocci G; Jacobs M; Vignetti M; Mandelli F; Efficace F
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):542-54. PubMed ID: 26324461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists.
    Stojkov I; Conrads-Frank A; Rochau U; Koinig KA; Arvandi M; Puntscher S; van Marrewijk C; Fenaux P; Symeonidis A; Chermat F; Garelius H; Bowen D; Mittelman M; Mora E; de Witte T; Efficace F; Siebert U; Stauder R
    Blood Adv; 2022 Jan; 6(1):1-12. PubMed ID: 34492684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indications for Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome.
    Danielson N; Byrne M
    Curr Hematol Malig Rep; 2020 Aug; 15(4):268-275. PubMed ID: 32125608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS?
    El-Jawahri A; Kim HT; Steensma DP; Cronin AM; Stone RM; Watts CD; Chen YB; Cutler CS; Soiffer RJ; Abel GA
    Bone Marrow Transplant; 2016 Aug; 51(8):1121-6. PubMed ID: 26999469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with hematopoietic cell transplantation (HCT) among patients in a population-based study of myelodysplastic syndrome (MDS) in Minnesota.
    Smith AR; Warlick ED; Roesler MA; Poynter JN; Richardson M; Nguyen P; Cioc A; Hirsch B; Ross JA
    Ann Hematol; 2015 Oct; 94(10):1667-75. PubMed ID: 26063191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
    Tiu RV; Sekeres MA
    Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia.
    Bryant AL; Drier SW; Lee S; Bennett AV
    Leuk Res; 2018 Jul; 70():106-116. PubMed ID: 29925044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolution of hematopoietic SCT in myelodysplastic syndrome.
    Kindwall-Keller T; Isola LM
    Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.
    Efficace F; Cottone F; Abel G; Niscola P; Gaidano G; Bonnetain F; Anota A; Caocci G; Cronin A; Fianchi L; Breccia M; Stauder R; Platzbecker U; Palumbo GA; Luppi M; Invernizzi R; Bergamaschi M; Borin L; Di Tucci AA; Zhang H; Sprangers M; Vignetti M; Mandelli F
    Cancer; 2018 Mar; 124(6):1251-1259. PubMed ID: 29231969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes.
    Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S39-43. PubMed ID: 27521322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
    Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome.
    Lee JH; Choi Y; Kim SD; Kim DY; Lee JH; Lee KH; Lee SM; Lee WS; Joo YD
    Eur J Haematol; 2015 Jun; 94(6):546-53. PubMed ID: 25315896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes in acute myeloid leukemia: Where are we now?
    Buckley SA; Kirtane K; Walter RB; Lee SJ; Lyman GH
    Blood Rev; 2018 Jan; 32(1):81-87. PubMed ID: 28888621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.